-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 11, Kexing Pharma announced its "marriage" with TOT BIOPHARM, and KEXING PHARMA has obtained Suzhou TOT BIOPHARM's bevacizumab in China, the EU (subject to EU member states in 2021), the UK, and the US.
, Exclusive commercialization license in all countries and regions around the world except Japan
.
Suzhou TOT's bevacizumab injection (trade name in mainland China: Pu Xinting) is a biosimilar of Roche's original drug Avastin, and was approved for marketing in mainland China on November 30, 2021 for the treatment of advanced stage , metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC) and metastatic colorectal cancer (mCRC)
.
The number of cancer patients worldwide is huge and the demand for this product is also very strong
.
According to IQVIA data, the global sales of bevacizumab injection in 2020 will be 6.
09 billion US dollars, of which sales in China will reach 3.
63 billion yuan
.
Kexing Pharmaceuticals is an innovative biopharmaceutical enterprise mainly engaged in the research, development, production and sales of recombinant protein drugs and microecological preparations.
And around the above therapeutic areas, there are certain traditional Chinese medicine and chemical medicine technology precipitation
.
This cooperation also means that Kexing Pharma has "another success" in the field of anti-tumor drugs
.
Previously, Kexing Pharmaceuticals has launched many layouts in the anti-tumor drug track
.
For example, in May 2021, Kexing Pharmaceuticals and Zhejiang Haichang Biotechnology "joined hands", and the two parties cooperated on the research and development project of HC007 for the treatment of metastatic breast cancer and other malignant tumors in the research and development product pipeline of Haichang Biotechnology
.
The content of cooperation includes cooperative development, commercialization, technology transfer, industrialization and so on of HC007
.
In July 2021, Sinovac and Maibotec successfully held the first batch of registration country confirmation and technical data handover ceremony for the commercialization of infliximab biosimilars (CMAB008) in overseas markets.
CMAB008 was also introduced by Sinovac.
Antibody drugs in the commercialization stage will further expand the company's product pipeline and improve the company's market layout
.
This product was approved by NMPA on July 14, 2021
.
It is mainly used to treat adult ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, Crohn's disease, fistula Crohn's disease, and psoriasis in adults and children over 6 years old
.
According to FiercePharma website data, in 2020, global sales of infliximab were $4.
195 billion
.
Behind Kexing Pharma's continuous cooperation with major companies, the company's overseas commercialization strength and achievements have been affirmed.
It is understood that the company has been actively deploying overseas markets for many years, the overseas sales network system has continued to expand, and exports to overseas countries are three.
More than ten
.
For the blockbuster antibody drugs in the commercialization stage introduced by this cooperation, Sinovac said that it will help Sinovac to expand its product pipeline, further improve the company's overseas market layout, and provide treatment options for unmet clinical needs
.
At the same time, laying a solid foundation for overseas sales for self-developed or future-introduced products is conducive to increasing overseas marketing channels, expanding overseas marketing scale, and enhancing the company's international influence
.
According to Frost & Sullivan data, the global antitumor drug market has shown a steady growth trend in recent years
.
The market size has reached US$143.
5 billion in 2019, and is expected to reach US$244.
4 billion by 2024, with a CAGR of 11.
2% from 2019 to 2024, and to reach US$391.
3 billion by 2030.
The compound annual growth rate from 2024 to 2030 The annual growth rate is 8.
2%
.
It is expected in the industry that for companies actively deploying in the anti-tumor drug market, with hard-core commercialization capabilities, and mature marketing systems at home and abroad, the future market prospects are promising
.
, Exclusive commercialization license in all countries and regions around the world except Japan
.
Suzhou TOT's bevacizumab injection (trade name in mainland China: Pu Xinting) is a biosimilar of Roche's original drug Avastin, and was approved for marketing in mainland China on November 30, 2021 for the treatment of advanced stage , metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC) and metastatic colorectal cancer (mCRC)
.
The number of cancer patients worldwide is huge and the demand for this product is also very strong
.
According to IQVIA data, the global sales of bevacizumab injection in 2020 will be 6.
09 billion US dollars, of which sales in China will reach 3.
63 billion yuan
.
Kexing Pharmaceuticals is an innovative biopharmaceutical enterprise mainly engaged in the research, development, production and sales of recombinant protein drugs and microecological preparations.
And around the above therapeutic areas, there are certain traditional Chinese medicine and chemical medicine technology precipitation
.
This cooperation also means that Kexing Pharma has "another success" in the field of anti-tumor drugs
.
Previously, Kexing Pharmaceuticals has launched many layouts in the anti-tumor drug track
.
For example, in May 2021, Kexing Pharmaceuticals and Zhejiang Haichang Biotechnology "joined hands", and the two parties cooperated on the research and development project of HC007 for the treatment of metastatic breast cancer and other malignant tumors in the research and development product pipeline of Haichang Biotechnology
.
The content of cooperation includes cooperative development, commercialization, technology transfer, industrialization and so on of HC007
.
In July 2021, Sinovac and Maibotec successfully held the first batch of registration country confirmation and technical data handover ceremony for the commercialization of infliximab biosimilars (CMAB008) in overseas markets.
CMAB008 was also introduced by Sinovac.
Antibody drugs in the commercialization stage will further expand the company's product pipeline and improve the company's market layout
.
This product was approved by NMPA on July 14, 2021
.
It is mainly used to treat adult ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, Crohn's disease, fistula Crohn's disease, and psoriasis in adults and children over 6 years old
.
According to FiercePharma website data, in 2020, global sales of infliximab were $4.
195 billion
.
Behind Kexing Pharma's continuous cooperation with major companies, the company's overseas commercialization strength and achievements have been affirmed.
It is understood that the company has been actively deploying overseas markets for many years, the overseas sales network system has continued to expand, and exports to overseas countries are three.
More than ten
.
For the blockbuster antibody drugs in the commercialization stage introduced by this cooperation, Sinovac said that it will help Sinovac to expand its product pipeline, further improve the company's overseas market layout, and provide treatment options for unmet clinical needs
.
At the same time, laying a solid foundation for overseas sales for self-developed or future-introduced products is conducive to increasing overseas marketing channels, expanding overseas marketing scale, and enhancing the company's international influence
.
According to Frost & Sullivan data, the global antitumor drug market has shown a steady growth trend in recent years
.
The market size has reached US$143.
5 billion in 2019, and is expected to reach US$244.
4 billion by 2024, with a CAGR of 11.
2% from 2019 to 2024, and to reach US$391.
3 billion by 2030.
The compound annual growth rate from 2024 to 2030 The annual growth rate is 8.
2%
.
It is expected in the industry that for companies actively deploying in the anti-tumor drug market, with hard-core commercialization capabilities, and mature marketing systems at home and abroad, the future market prospects are promising
.
